Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity

BACKGROUND AND PURPOSE: The lack of a new effective treatment for small cell lung cancer (SCLC) is an unresolved problem. Due to the new identification of delta-like ligand 3 (DLL3) and its high expression in SCLC patients, the use of DLL3 in target therapy can be effective. The use of bacterial tox...

Descripción completa

Detalles Bibliográficos
Autores principales: Ataee, Mohammad Hossein, Mirhosseini, Seyed Ali, Mirnejad, Reza, Rezaie, Ehsan, Hosseini, Hamideh Mahmoodzadeh, Amani, Jafar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400466/
https://www.ncbi.nlm.nih.gov/pubmed/36034078
http://dx.doi.org/10.4103/1735-5362.350243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400466/
https://www.ncbi.nlm.nih.gov/pubmed/36034078
http://dx.doi.org/10.4103/1735-5362.350243

Ejemplares similares